Analysts' ratings for Quest Diagnostics DGX over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 6 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 3 | 0 | 0 |
| 3M Ago | 0 | 0 | 2 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $146.57, along with a high estimate of $160.00 and a low estimate of $137.00. Observing a 4.91% increase, the current average has risen from the previous average price target of $139.71.
Investigating Analyst Ratings: An Elaborate Study
The standing of Quest Diagnostics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Macdonald | Truist Securities | Lowers | Hold | $145.00 | $150.00 |
| David Macdonald | Truist Securities | Raises | Hold | $150.00 | $145.00 |
| Derik De Bruin | B of A Securities | Raises | Buy | $160.00 | $140.00 |
| Patrick Donnelly | Citigroup | Raises | Neutral | $145.00 | $130.00 |
| Kevin Caliendo | UBS | Raises | Neutral | $137.00 | $135.00 |
| John Stansel | JP Morgan | Raises | Neutral | $149.00 | $148.00 |
| David Westenberg | Piper Sandler | Raises | Neutral | $140.00 | $130.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Quest Diagnostics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Quest Diagnostics compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Quest Diagnostics's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Quest Diagnostics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Quest Diagnostics analyst ratings.
Get to Know Quest Diagnostics Better
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Financial Milestones: Quest Diagnostics's Journey
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Challenges: Quest Diagnostics's revenue growth over 3 months faced difficulties. As of 30 September, 2023, the company experienced a decline of approximately -7.68%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Quest Diagnostics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.72%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.52%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Quest Diagnostics's ROA excels beyond industry benchmarks, reaching 1.66%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.76.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
